inflammation in the pathogenesis of microvascular complications in diabetes

Clicks: 228
ID: 199521
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #189 of 262 articles by views in aip advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 262 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Diabetes and hyperglycemia create a proinflammatory microenvironment that progresses to microvascular complications such as nephropathy, retinopathy, and neuropathy. Diet-induced insulin resistance is a potential initiator of this change in Type 2 diabetes (T2D) which can increase adipokines and generate a chronic low-grade inflammatory state. The advanced glycation end-products (AGEs) AGE receptor (RAGE) axis, reactive oxygen species, and hypoxia can also interact to worsen complications. Numerous efforts have gained way to understanding the mechanisms of these modulators and attenuation of the inflammatory response, however effective treatments have still not emerged. The complexity of inflammatory signaling may suggest a need for multi-targeted therapy. This review presents recent findings aimed at new treatment strategies.
Reference Key
nguyen2012frontiersinflammation Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Dung Van Nguyen;Lynn eShaw;Maria eGrant
Journal aip advances
Year 2012
DOI
10.3389/fendo.2012.00170
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.